Brett van Leer Greenberg, MD
Gastroenterology · Summerville, SCNPI 1871911867
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $29,180 of the $44,892 with a category attached, or 65.0%. Phathom Pharmaceuticals, Inc. accounts for 68.5% of it on its own, with 26 other manufacturers making up the rest. Reporting peaked in 2024 at $26,787 and has fallen 53.0% since, to $12,577 in 2025. Among gastroenterology clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 194 payments — averaging $231.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$31K
- Sanofi$10K
- AbbVie$1K
- Intra-sana Laboratories$900
- Redhill Biopharma Inc.$577
- Janssen Scientific Affairs, LLC$247
- plus $2K from 21 others
Across 202 payments — averaging $5299.64 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$621K
- Boehringer Ingelheim International GmbH$273K
- Bausch Health US, LLC$55K
- Regeneron$46K
- Takeda Pharmaceuticals U.S.A., Inc.$38K
- AbbVie$37K
What the payments were for
- Consulting fees$8,60119%
- Speaking & faculty fees$29,18065%
- Travel & lodging$1,3113%
- Food & beverage$5,74013%
- Education$70%
- Gifts$520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 42 | $30,759 |
| Sanofi | 19 | $9,694 |
| AbbVie | 59 | $1,123 |
| Intra-sana Laboratories | 2 | $900 |
| Redhill Biopharma Inc. | 5 | $577 |
| Janssen Scientific Affairs, LLC | 2 | $247 |
| Medtronic | 3 | $210 |
| Johnson & Johnson | 6 | $193 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 10 | $172 |
| Regeneron Healthcare Solutions, Inc. | 2 | $166 |
| Gilead | 5 | $125 |
| Pfizer | 6 | $119 |
| Nestle Healthcare Nutrition Inc. | 5 | $102 |
| Braintree Laboratories, Inc. | 5 | $68 |
| Boston Scientific | 3 | $59 |
| Celltrion USA Inc. | 3 | $53 |
| Novo Nordisk | 2 | $51 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Axonics, Inc. | 3 | $46 |
| Bristol Myers Squibb | 2 | $32 |
| Ferring Pharmaceuticals Inc. | 1 | $27 |
| Covidien LP | 1 | $27 |
| QOL Medical, LLC | 1 | $26 |
| Merck | 2 | $25 |
| Alnylam Pharmaceuticals Inc. | 1 | $16 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Cook Medical LLC | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VOQUEZNA$30,370
- DUPIXENT$2,431
- Reltone 200 Mg$900
- Reltone 400 Mg$900
- Talicia$440
- Tremfya$246
- STELARA$125
- EndoFlip$115
- Skyrizi$113
- Rinvoq$110
How this compares
$44,892 in reported general payments places this provider in the 90th percentile of 259 gastroenterology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VoqueznaVonoprazan Fumarate | 13 | $11,199 |
| Ursodiol | 25 | $5,261 |
| Omeprazole | 140 | $3,711 |
| Budesonide DrBudesonide | 11 | $860 |
| Pantoprazole Sodium | 57 | $827 |
| Famotidine | 38 | $793 |
| Sucralfate | 13 | $784 |
| Dicyclomine Hcl | 11 | $414 |
| Fluconazole | 12 | $211 |
| Spironolactone | 13 | $204 |
| Furosemide | 13 | $44 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Phathom Pharmaceuticals, Inc.Voquezna | $30,759 | $11,19913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 259 gastroenterology providers in South Carolina.
Other gastroenterology in Summerville
- Chuma ObinemeSummerville$11K
- Erin ForsterCharleston$788K
- Mark DeleggeCharleston$568K
- Nathan ShoresCharleston$217K
- Andre EaddyGreenville$212K
- Alejandro SuarezCharleston$210K
- Veeral OzaGreenville$199K
- Peter CottonCharleston$193K
- Christina BauerGreenville$179K
- Andrew PearsonMyrtle Beach$166K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.